Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Assessing the Prognostic Factors, Survival, and Recurrence Incidence of Triple Negative Breast Cancer Patients, a Single Center Study in Iran Publisher Pubmed



Mousavi SA1 ; Kasaeian A2 ; Pourkasmaee M1 ; Ghavamzadeh A1 ; Alimoghaddam K1 ; Vaezi M1 ; Fumani HK1 ; Babakhani D1 ; Tavakoli S1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Deptartment of Biostatistics and Epidemiology, Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran

Source: PLoS ONE Published:2019


Abstract

Background Breast cancer is the second leading cause of death due to cancer in women. Triple negative breast cancer (TNBC) is a subgroup with unique behavior. There is a controversy in organ involvement in metastasis. In this study, we planned to define the prognostic factors, survival, and recurrence incidence of patients. Materials and method Among the 583 patients with breast mass referred to hematology and oncology clinic in Shariati hospital, Tehran, Iran from March 2005 to March 2015, fifty four patients entered the survival analysis whom we followed for two years until March 2017. Overall survival (OS) and disease-free survival (DFS) and Cumulative recurrence incidences (RI) were estimated. Univariate and multivariate Cox proportional hazards regression was performed to assess risk factors in predicting OS and DFS. Results Median follow up for the patients was 5.00 years. The five-year OS, DFS and RI were 86.13% (95% CI (71.42–93.59), 63.09% (95% CI (47.04–75.49) and 32.15% (95% CI (19.52–47.43) respectively. Among the factors studied OS, DFS and RI differed significantly only between patients with and without nodal involvement (P = 0.004, P = 0.003, and P = 0.02 respectively). On the other hand, based on the univariate modeling, patients with nodal involvement had a higher risk of breast cancer-specific death (HR: 17.99, P = 0.004). Furthermore, patients with nodal involvement had a higher risk of breast cancer-specific death or recurrence (HR = 5.64, P = 0.008). In Multivariate model, just the nodal involvement significantly changed the hazard for OS (HR = 23.91, P = 0.001). As the nodal involvement was the only significant risk factor at the 0.2 level of significance, we can consider the hazard ratio of lymph node positivity in DFS univariate models as adjusted hazard. Conclusion The only factor with significant effect on OS, DFS and RI was nodal involvement in the pathology report. © 2019 Mousavi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Other Related Docs
12. Breast Cancer: Biology, Biomarkers, and Treatments, International Immunopharmacology (2020)
17. Personalized Medicine in Breast Cancer: Pharmacogenomics Approaches, Pharmacogenomics and Personalized Medicine (2019)